These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38431050)

  • 1. Effect of Corticosteroids on Long-Term Humoral and Memory T-Cell Responses in Follow-Up Visit of Hospitalized Patients With COVID-19.
    Wang Y; Guo L; Fan G; Han Y; Zhang Q; Wang W; Ren L; Zhang H; Wang G; Zhang X; Huang T; Chen L; Huang L; Gu X; Cui D; Wang X; Zhong J; Wang Y; Li H; Huang C; Wang J; Cao B
    Chest; 2024 Aug; 166(2):281-293. PubMed ID: 38431050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study.
    Guo L; Wang G; Wang Y; Zhang Q; Ren L; Gu X; Huang T; Zhong J; Wang Y; Wang X; Huang L; Xu L; Wang C; Chen L; Xiao X; Peng Y; Knight JC; Dong T; Cao B; Wang J
    Lancet Microbe; 2022 May; 3(5):e348-e356. PubMed ID: 35345417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients.
    Mohn KG; Bredholt G; Zhou F; Madsen A; Onyango TB; Fjelltveit EB; Jalloh SL; Brokstad KA; Cantoni D; Mayora-Neto M; Temperton N; Langeland N; Cox RJ;
    PLoS One; 2022; 17(2):e0261979. PubMed ID: 35192617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence of Antibody and Cellular Immune Responses in Coronavirus Disease 2019 Patients Over Nine Months After Infection.
    Yao L; Wang GL; Shen Y; Wang ZY; Zhan BD; Duan LJ; Lu B; Shi C; Gao YM; Peng HH; Wang GQ; Wang DM; Jiang MD; Cao GP; Ma MJ
    J Infect Dis; 2021 Aug; 224(4):586-594. PubMed ID: 33978754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2-specific B- and T-cell immunity in a population-based study of young Swedish adults.
    Björkander S; Du L; Zuo F; Ekström S; Wang Y; Wan H; Sherina N; Schoutens L; Andréll J; Andersson N; Georgelis A; Bergström A; Marcotte H; Kull I; Hammarström L; Melén E; Pan-Hammarström Q;
    J Allergy Clin Immunol; 2022 Jan; 149(1):65-75.e8. PubMed ID: 34695490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.
    Havervall S; Ng H; Jernbom Falk A; Greilert-Norin N; Månberg A; Marking U; Laurén I; Gabrielsson L; Salomonsson AC; Aguilera K; Kihlgren M; Månsson M; Rosell A; Hellström C; Andersson E; Olofsson J; Skoglund L; Yousef J; Pin E; Lord M; Åberg M; Hedhammar M; Tegel H; Dönnes P; Phillipson M; Nilsson P; Klingström J; Mangsbo S; Hober S; Thålin C
    J Intern Med; 2022 Jan; 291(1):72-80. PubMed ID: 34459525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4
    Marklund E; Leach S; Nyström K; Lundgren A; Liljeqvist JÅ; Nilsson S; Yilmaz A; Andersson LM; Bemark M; Gisslén M
    Front Immunol; 2021; 12():750448. PubMed ID: 34795668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People.
    Demaret J; Corroyer-Simovic B; Alidjinou EK; Goffard A; Trauet J; Miczek S; Vuotto F; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Labreuche J; Sobaszek A; Hisbergues M; Puisieux F; Labalette M; Lefèvre G
    Front Immunol; 2021; 12():778679. PubMed ID: 34868051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
    Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
    Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Function Is More Reliable than Quantity to Follow Up the Humoral Response to the Receptor-Binding Domain of SARS-CoV-2-Spike Protein after Natural Infection or COVID-19 Vaccination.
    Sariol CAA; Pantoja P; Serrano-Collazo C; Rosa-Arocho T; Armina-Rodríguez A; Cruz L; Stone ETT; Arana T; Climent C; Latoni G; Atehortua D; Pabon-Carrero C; Pinto AKK; Brien JDD; Espino AMM
    Viruses; 2021 Sep; 13(10):. PubMed ID: 34696403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of SARS-CoV-2 Immunity in Convalescent Children and Adolescents.
    Tsang HW; Chua GT; To KKW; Wong JSC; Tu W; Kwok JSY; Wong WHS; Wang X; Zhang Y; Rosa Duque JS; Chan GCF; Chu WK; Pang CP; Tam PKH; Lau YL; Wong ICK; Leung WH; Yuen KY; Kwan MYW; Ip P
    Front Immunol; 2021; 12():797919. PubMed ID: 34975908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade.
    Masiá M; Fernández-González M; García JA; Padilla S; García-Abellán J; Botella Á; Mascarell P; Agulló V; Gutiérrez F
    EBioMedicine; 2022 Aug; 82():104153. PubMed ID: 35816896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and immunological outcomes of SARS-CoV-2-infected vaccine responders, vaccine non-responders, and unvaccinated patients evaluated for neutralizing monoclonal antibody treatment at a single German tertiary care center: a retrospective cohort study with prospective follow-up.
    Triebelhorn J; Schneider J; Spinner CD; Iakoubov R; Voit F; Wagner L; Erber J; Rothe K; Berthele A; Pernpeintner V; Strauß EM; Renders L; Willmann A; Minic M; Vogel E; Christa C; Hoffmann D; Protzer U; Jeske SD
    Infection; 2024 Jun; 52(3):1143-1151. PubMed ID: 38305828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study.
    He Z; Ren L; Yang J; Guo L; Feng L; Ma C; Wang X; Leng Z; Tong X; Zhou W; Wang G; Zhang T; Guo Y; Wu C; Wang Q; Liu M; Wang C; Jia M; Hu X; Wang Y; Zhang X; Hu R; Zhong J; Yang J; Dai J; Chen L; Zhou X; Wang J; Yang W; Wang C
    Lancet; 2021 Mar; 397(10279):1075-1084. PubMed ID: 33743869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection.
    Pradenas E; Trinité B; Urrea V; Marfil S; Tarrés-Freixas F; Ortiz R; Rovirosa C; Rodon J; Vergara-Alert J; Segalés J; Guallar V; Valencia A; Izquierdo-Useros N; Noguera-Julian M; Carrillo J; Paredes R; Mateu L; Chamorro A; Toledo R; Massanella M; Clotet B; Blanco J
    Cell Rep Med; 2022 Feb; 3(2):100523. PubMed ID: 35233547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durable antibody response one year after hospitalization for COVID-19: A longitudinal cohort study.
    Masiá M; Fernández-González M; Telenti G; Agulló V; García JA; Padilla S; García-Abellán J; Galiana A; Gonzalo-Jiménez N; Gutiérrez F
    J Autoimmun; 2021 Sep; 123():102703. PubMed ID: 34303083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses.
    Balachandran H; Phetsouphanh C; Agapiou D; Adhikari A; Rodrigo C; Hammoud M; Shrestha LB; Keoshkerian E; Gupta M; Turville S; Christ D; King C; Sasson SC; Bartlett A; Grubor-Bauk B; Rawlinson W; Aggarwal A; Stella AO; Klemm V; Mina MM; Post JJ; Hudson B; Gilroy N; Konecny P; Ahlenstiel G; Dwyer DE; Sorrell TC; Kelleher A; Tedla N; Lloyd AR; Martinello M; Bull RA;
    Cell Rep; 2022 Feb; 38(6):110345. PubMed ID: 35090598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Robust and Functional Immune Memory Up to 9 Months After SARS-CoV-2 Infection: A Southeast Asian Longitudinal Cohort.
    Vo HTM; Maestri A; Auerswald H; Sorn S; Lay S; Seng H; Sann S; Ya N; Pean P; Dussart P; Schwartz O; Ly S; Bruel T; Ly S; Duong V; Karlsson EA; Cantaert T
    Front Immunol; 2022; 13():817905. PubMed ID: 35185909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.